Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial by Seini Moimoi | Nov 3, 2022 | Portfolio News
Longitude Capital Promotes Carolyn Helms, Chief Financial Officer, to Managing Director by Seini Moimoi | Nov 2, 2022 | Longitude Capital News
Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database by Seini Moimoi | Oct 31, 2022 | Portfolio News
Axonics® Reports Third Quarter 2022 Financial Results by Seini Moimoi | Oct 31, 2022 | Portfolio News
Vaxcyte Reports Positive Topline Data from Phase 1/2 Proof-of-Concept Study of its 24-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Pneumococcal Disease in Adults Aged 18-64 by Seini Moimoi | Oct 24, 2022 | Portfolio News
Cohere Health and Humana Expand Partnership to Further Improve Physician and Member Experiences by Seini Moimoi | Oct 24, 2022 | Portfolio News
Tricida Announces $125 Million Debt Facility with Hercules Capital by Seini Moimoi | Oct 19, 2022 | Portfolio News
LEXEO Therapeutics Receives Orphan Drug Designation for LX1004 from European Commission by Seini Moimoi | Oct 18, 2022 | Portfolio News
Rapid Micro Biosystems Announces RMBNucleus™ Mold Alarm for the Growth Direct® System by Seini Moimoi | Oct 10, 2022 | Portfolio News
Theseus Pharmaceuticals Nominates THE-349, a Fourth-Generation EGFR Inhibitor Development Candidate in Non-Small Cell Lung Cancer by Seini Moimoi | Oct 3, 2022 | Portfolio News
